AFFiRiS AG Email Format

Biotechnology ResearchWien, Austria2-10 Employees

AFFiRiS AG is a clinical-stage biotechnology company based in Vienna, Austria, focused on neurodegenerative diseases. It seeks to address unmet medical needs by developing therapies that intervene at the disease’s root causes rather than simply treating symptoms. The company’s approach, Specific Active ImmunoTherapy, aims to mobilize the body's immune system to target proteins central to disease progression, leveraging its AFFITOME platform to optimize immune responses and potentially address multiple pathogenic proteins within a single disease setting, with an expectation of durable activity and infrequent dosing. 

Its portfolio includes immunotherapy candidates in both clinical development and preclinical stages for conditions such as Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, and Huntington’s disease. AFFiRiS positions itself within the biotechnology research space by pursuing therapies that modulate disease mechanisms rather than provide symptomatic care, aided by a small, specialized team. In December 2021, the company announced an exclusive collaboration and license agreement with Frontier Biotechnologies Inc., marking a concrete external partnership to advance its programs.

Sign up for free to view info

Company overview Employee directory